Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?
Sedef AM, Köse F, Sümbül AT, Doğan Ö, Beşen AA, Tatlı AM, Mertsoylu H, Sezer A, Muallaoğlu S, Özyılkan Ö, Abalı H. Sedef AM, et al. Among authors: tatli am. Med Oncol. 2015 Feb;32(2):476. doi: 10.1007/s12032-014-0476-8. Epub 2015 Jan 9. Med Oncol. 2015. PMID: 25572818
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Bilgin B, et al. Among authors: tatli am. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433657
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS, Tatlı AM, Geredeli Ç, Atcı M, Besen AA, Mertsoylu H, Uysal M, Özdoğan M, Aydın SG, Bilici A, Karaağaç M, Artaç M, Kaplan MA, Ebinç S, Coşkun HŞ. Göksu SS, et al. Among authors: tatli am. Cancer Chemother Pharmacol. 2021 Nov;88(5):805-812. doi: 10.1007/s00280-021-04328-9. Epub 2021 Jul 26. Cancer Chemother Pharmacol. 2021. PMID: 34312705
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: tatli am. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31. J Cancer Res Clin Oncol. 2022. PMID: 34331582
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y, Tatli AM, Teker F, Onder AH, Kose F, Geredeli C, Karaagac M, Kaplan MA, Inanc M, Goktas Aydin S, Kargi A, Arak H, Ozturk B, Besen AA, Selvi O, Korkmaz M, Oruc Z, Bozkurt O, Bilici A, Bayram S, Dae SA, Ozdogan M, Coskun HS, Sezgin Goksu S. Ilhan Y, et al. Among authors: tatli am. Int J Gynecol Cancer. 2022 Apr 4;32(4):502-507. doi: 10.1136/ijgc-2021-003165. Int J Gynecol Cancer. 2022. PMID: 35086927
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Gursoy P, et al. Among authors: tatli am. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875. doi: 10.1007/s00432-022-03984-5. Epub 2022 Apr 5. J Cancer Res Clin Oncol. 2023. PMID: 35381885
54 results